TD Cowen lowered the firm’s price target on Guardant Health to $37 from $44 and keeps an Outperform rating on the shares. The firm said they view the guide as conservative but see the base business is undervalued, ast investors will need patience to let screening play out.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on GH:
- Guardant Health Announces Board Member Samir Kaul’s Resignation
- Guardant Health price target lowered to $54 from $64 at Craig-Hallum
- Guardant Health’s preliminary Q4 results well ahead of consensus, says Canaccord
- Guardant Health sees FY23 revenue $562M-$563M, consensus $555.18M
- Guardant Health reports preliminary Q4 revenue $153M-$154M, consensus $146.34M
